Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> GPCR/G protein >> Ras

Ras

Ras belongs to a class of small GTPase and is involved in transmitting signals within cells.

Products for  Ras

  1. Cat.No. Product Name Information
  2. GC73101 (4S)-PROTAC SOS1 degrader-1 diTFA (4S)-PROTAC SOS1 degrader-1 (diTFA) is a potent PROTAC SOS1 degrader. (4S)-PROTAC SOS1 degrader-1 diTFA Chemical Structure
  3. GC64657 (E/Z)-ZINC09659342 (E/Z)-ZINC09659342 is an inhibitor of Lbc-RhoA interaction. (E/Z)-ZINC09659342 Chemical Structure
  4. GC19541 (rac)-Antineoplaston A10

    (rac)-Antineoplaston A10 is the racemate of Antineoplaston A10

     (rac)-Antineoplaston A10 Chemical Structure
  5. GC69904 (S)-JDQ-443

    (S)-NVP-JDQ443

    (S)-JDQ-443 is an isomer of JDQ-443. JDQ-443 is an orally effective and selective covalent KRAS G12C inhibitor. JDQ-443 has anti-tumor activity.

     (S)-JDQ-443 Chemical Structure
  6. GC32770 1A-116 1A-116, a potent Rac1 inhibitor, is specific for W56 residues, can prevent EGF-induced Rac1 activation and block Rac1-P-Rex1 interaction. 1A-116 can induce apoptosis and inhibit cell proliferation, migration and cycle progression in a concentration-dependent manner. 1A-116 also demonstrates a high antimetastatic activity in vivo. 1A-116 Chemical Structure
  7. GC72854 6-CEPN 6-CEPN is a RAS inhibitor. 6-CEPN Chemical Structure
  8. GC15478 6H05 K-Ras inhibitor 6H05 Chemical Structure
  9. GC60533 6H05 (TFA) An allosteric inhibitor of oncogenic K-Ras(G12C) 6H05 (TFA) Chemical Structure
  10. GC34427 6H05 trifluoroacetate (K-Ras inhibitor) 6H05 trifluoroacetate (K-Ras inhibitor) Chemical Structure
  11. GC73765 ADT-007 ADT-007 is a potent and orally active pan-RAS inhibitor with strong anticancer effects. ADT-007 Chemical Structure
  12. GC19546 AMG-510 racemate AMG-510 is the first KRAS G12C inhibitor in clinical development and leads to the regression of KRAS G12C tumors. AMG-510 racemate Chemical Structure
  13. GC35361 Antineoplaston A10 Antineoplaston A10, a naturally occurring substance in human body, is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer. Antineoplaston A10 Chemical Structure
  14. GC73240 ARN22089 ARN22089 is a oral active novel class of trisubstituted pyrimidine, blocks the interaction of CDC42 GTPases with specific downstream effectors. ARN22089 Chemical Structure
  15. GC34114 ARS-1323 ARS-1323, the racemate of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1. ARS-1323 Chemical Structure
  16. GC65480 ARS-1323-alkyne ARS-1323-alkyne, a switch-II pocket (S-IIP) inhibitor, is a conformational specific chemical reporter of KRASG12C nucleotide state in living cells. ARS-1323-alkyne Chemical Structure
  17. GC34055 ARS-1620 ARS-1620 is an atropisomeric selective KRASG12C inhibitor with desirable pharmacokinetics. ARS-1620 Chemical Structure
  18. GC34091 ARS-1630 ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1. ARS-1630 Chemical Structure
  19. GC19037 ARS-853 ARS-853 is a selective, covalent KRASG12C inhibitor with an IC50 of 2.5 uM. ARS-853 Chemical Structure
  20. GC64341 ASP2453 ASP2453 is a potent, selective and covalent KRAS G12C inhibitor. ASP2453 inhibits the Son of Sevenless (SOS)-mediated interaction between KRAS G12C and Raf with an IC50 value of 40 nM. ASP2453 Chemical Structure
  21. GC46893 Atranorin

    NSC 87512, NSC 249980, NSC 685591

     A depside lichen metabolite with diverse biological activities Atranorin Chemical Structure
  22. GC68708 Atrovastatin-PEG3-FITC

    Atorvastatin-PEG3-FITC (compound S31) is a KRAS-PDEδ interaction inhibitor. Atorvastatin-PEG3-FITC can act as a ligand in fluorescence anisotropy assays.

     Atrovastatin-PEG3-FITC Chemical Structure
  23. GC72868 AZA197 AZA197 is a selective small molecule inhibitor of Cdc42. AZA197 Chemical Structure
  24. GC73533 AZD4747 AZD4747 is a selective, blood-brain barrier-permeable mutant GTPase KRASG12C inhibitor. AZD4747 Chemical Structure
  25. GC33186 BAY-293 An inhibitor of the K-Ras-SOS1 protein-protein interaction BAY-293 Chemical Structure
  26. GC73788 BBO-8520 BBO-8520 is a direct small molecule covalent inhibitor targeting KRAS G12C with high oral availability. BBO-8520 Chemical Structure
  27. GC33340 BDP9066 BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC50 of 64 nM for MRCKβ in SCC12 cells, Ki values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation. BDP9066 Chemical Structure
  28. GC73160 BI-0474 BI-0474 is a potent KRASG12C inhibitor with an IC50 value of 7.0 nM for the GDP-KRAS::SOS1 protein-protein interaction. BI-0474 Chemical Structure
  29. GC73477 BI-2493 BI-2493 is a structural analogue of BI-2865 and a highly selective and orally active pan-KRAS inhibitor. BI-2493 Chemical Structure
  30. GC35513 BI-2852

    BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based drug design with nanomolar affinity.

    BI-2852 Chemical Structure
  31. GC68760 BI-2865

    BI-2865 is a non-covalent pan-KRAS inhibitor. BI-2865 binds to KRAS WT, G12C, G12D, G12V and G13D mutants with KD values of 6.9, 4.5, 32, 26 and 4.3 nM respectively. BI-2865 inhibits the proliferation of BaF3 cells expressing KRAS G12C, G12D or G12V mutations (average IC50: approximately 140 nM).

     BI-2865 Chemical Structure
  32. GC10612 BQU57 Derivative of RBC8 BQU57 Chemical Structure
  33. GC16692 Casin

    Pirl1-related Compound 2

     GTPase Cdc42 inhibitor Casin Chemical Structure
  34. GC14266 CCG 203971

    Antifibrotic agent

     CCG 203971 Chemical Structure
  35. GC12795 CCG-1423 RhoA inhibitor CCG-1423 Chemical Structure
  36. GC38898 CCG-222740 CCG-222740 is an orally active and selective Rho/myocardin-related transcription factor (MRTF) pathway inhibitor. CCG-222740 is also a potent inhibitor of alpha-smooth muscle actin protein expression. CCG-222740 effectively reduces fibrosis in skin and blocks melanoma metastasis. CCG-222740 Chemical Structure
  37. GC12948 CID-1067700

    ML-282

    competitive inhibitor of nucleotide binding by Ras-related GTPases

     CID-1067700 Chemical Structure
  38. GC62347 CMC2.24

    TRB-N0224

     CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting Ras activation and its downstream effector ERK1/2 pathway. CMC2.24 Chemical Structure
  39. GC73892 DCC-3116 DCC-3116 is an orally active ULK1/2 inhibitor. DCC-3116 Chemical Structure
  40. GC13076 Deltarasin A KRAS inhibitor Deltarasin Chemical Structure
  41. GC12060 Deltarasin hydrochloride inhibitor of KRAS-PDEδ interaction, potent and selective Deltarasin hydrochloride Chemical Structure
  42. GC35859 Diazepinomicin

    ECO-4601; TLN-4601; BU 4664L

     Diazepinomicin (TLN-4601) is a secondary metabolite produced by Micromonospora sp. Diazepinomicin (TLN-4601) inhibits the EGF-induced Ras-ERK MAPK signaling pathway and induces apoptosis. An anti-tumor agent for K-Ras mutant models. Diazepinomicin Chemical Structure
  43. GC65270 Digeranyl bisphosphonate

    DGBP

     Digeranyl bisphosphonate (DGBP) is a potent geranylgeranylpyrophosphate (GGPP) synthase inhibitor, which inhibits geranylgeranylation of Rac1. Digeranyl bisphosphonate Chemical Structure
  44. GC10030 EHop-016 Rac1/Rac3 GTPase inhibitor,potent and specific EHop-016 Chemical Structure
  45. GC10660 EHT 1864 Rac family small GTPases inhibitor EHT 1864 Chemical Structure
  46. GC66473 ESI-08 ESI-08 is a potent and selective EPAC antagonist, which can completely inhibit both EPAC1 and EPAC2 (IC50 of 8.4 μM) activity. ESI-08 selectively blocks cAMP-induced EPAC activation, but does not inhibit cAMP-mediated PKA activation. ESI-08 Chemical Structure
  47. GC64723 Garsorasib

    D-1553

     Garsorasib is a potent inhibitor of KRAS G12C with an IC50 of 10 nM. Garsorasib has the potential for the research of various cancer such as pancreatic cancer, endometrial cancer, colorectal cancer, or lung cancer (non-small cell lung cancer) (extracted from patent WO2020233592A1, compound 2). Garsorasib Chemical Structure
  48. GC64510 GDC-6036 GDC-6036 (compound 17a) is a potent K-Ras G12C inhibitor with an IC50 of <0.01 μM. GDC-6036 has an EC50 of 2 nM in K-Ras G12C-alkylation HCC1171 cells. GDC-6036 Chemical Structure
  49. GC68004 GDC-6036-NH GDC-6036-NH Chemical Structure
  50. GC64216 GGTI-286 GGTI-286, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276. GGTI-286 selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s =2 and >30 μM, respectively). GGTI-286 also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM. GGTI-286 Chemical Structure
  51. GC64784 GGTI-286 hydrochloride GGTI-286 hydrochloride, a potent GGTase I inhibitor, is 25-fold more potent (IC50=2 μM) than the corresponding methyl ester of FTI-276. GGTI-286 hydrochloride selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC50s =2 and >30 μM, respectively). GGTI-286 hydrochloride also potently inhibits oncogenic K-Ras4B stimulation with an IC50 of 1 μM. GGTI-286 hydrochloride Chemical Structure
  52. GC36134 GGTI298 GGTI298 is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, strongly inhibiting the processing of geranylgeranylated Rap1A with little effect on processing of farnesylated Ha-Ras, with IC50 values of 3 and > 20 μM in vivo, respectively. GGTI298 Chemical Structure
  53. GC19164 GGTI298 Trifluoroacetate

    GGTI298 Trifluoroacetate is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, which can inhibit Rap1A with IC50 of 3 uM; little effect on Ha-Ras with IC50 of >20 uM.

     GGTI298 Trifluoroacetate Chemical Structure
  54. GC63564 JDQ-443

    NVP-JDQ443

     JDQ-443 is an orally active, potent, selective, and covalent KRAS G12C inhibitor (extracted from patent WO2021120890A1). JDQ-443 shows antitumor activity. JDQ-443 Chemical Structure
  55. GC36398 K-Ras G12C-IN-1 K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1. K-Ras G12C-IN-1 Chemical Structure
  56. GC36399 K-Ras G12C-IN-2 K-Ras G12C-IN-2 is an irreversible covalent K-Ras G12C inhibitor. K-Ras G12C-IN-2 Chemical Structure
  57. GC36400 K-Ras G12C-IN-3 K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C. K-Ras G12C-IN-3 Chemical Structure
  58. GC62622 K-Ras G12C-IN-4 K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRASG12C. K-Ras G12C-IN-4 Chemical Structure
  59. GC12247 K-Ras(G12C) inhibitor 12 allosteric inhibitor of K-Ras(G12C) K-Ras(G12C) inhibitor 12 Chemical Structure
  60. GC33153 K-Ras-IN-1 K-Ras-IN-1 is a K-Ras inhibitor. K-Ras-IN-1 binds to K-Ras (WT), K-Ras (G12D), K-Ras (G12V), and H-Ras. K-Ras-IN-1 has potential for the research of pancreatic, colon and lung carcinomas. K-Ras-IN-1 Chemical Structure
  61. GC16922 Kobe0065 Ras inhibitor Kobe0065 Chemical Structure
  62. GC11204 kobe2602 Ras inhibitor kobe2602 Chemical Structure
  63. GC64558 KRA-533 KRA-533 is a potent KRAS agonist. KRA-533 binds to the GTP/GDP binding pocket in the KRAS protein to prevent GTP cleavage, resulting in the accumulation of constitutively active GTP-bound KRAS that triggers both apoptotic and autophagic cell death pathways in cancer cells. KRA-533 Chemical Structure
  64. GC34198 KRas G12C inhibitor 1 KRas G12C inhibitor 1 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1. KRas G12C inhibitor 1 Chemical Structure
  65. GC36397 KRAS G12C inhibitor 13 KRAS G12C inhibitor 13 is a KRAS G12C inhibitor extracted from patent WO2018143315A1, compound 30. KRAS G12C inhibitor 13 Chemical Structure
  66. GC64442 KRAS G12C inhibitor 14 KRAS G12C inhibitor 14 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 17, has an IC50 of 18 nM. KRAS G12C inhibitor 14 Chemical Structure
  67. GC63875 KRAS G12C inhibitor 15 KRAS G12C inhibitor 15 is a potent KRAS G12C inhibitor extracted from patent WO2019110751A1, compound 22, has an IC50 of 5 nM. KRAS G12C inhibitor 15 Chemical Structure
  68. GC69338 KRAS G12C inhibitor 19

    KRAS G12C inhibitor 19 is an effective inhibitor of KRAS G12C. It significantly inhibits tumor growth (information from patent WO2021118877A1).

     KRAS G12C inhibitor 19 Chemical Structure
  69. GC34188 KRas G12C inhibitor 2 KRas G12C inhibitor 2 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1. KRas G12C inhibitor 2 Chemical Structure
  70. GC65904 KRAS G12C inhibitor 28 KRAS G12C inhibitor 28 is a KRAS G12C inhibitor with an IC50 of 57 nM. KRAS G12C inhibitor 28 has antitumor effects (WO2021113595A1; Example 1). KRAS G12C inhibitor 28 Chemical Structure
  71. GC34196 KRas G12C inhibitor 3 KRas G12C inhibitor 3 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1. KRas G12C inhibitor 3 Chemical Structure
  72. GC34192 KRas G12C inhibitor 4 KRas G12C inhibitor 1 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1. KRas G12C inhibitor 4 Chemical Structure
  73. GC34162 KRAS G12C inhibitor 5 KRAS G12C inhibitor 5 is a KRas G12C inhibitor extracted from patent WO2017201161A1, Compound example 147. KRAS G12C inhibitor 5 Chemical Structure
  74. GC62227 KRAS G12D inhibitor 1 KRAS G12D inhibitor 1 (example 243) is a KRAS G12D inhibitor, with an IC50 of 0.8 nM for KRAS G12D-mediated ERK phosphorylation. KRAS G12D inhibitor 1 Chemical Structure
  75. GC69339 KRAS G12D inhibitor 14

    KRAS G12D inhibitor 14 is an effective inhibitor of KRAS G12D, with a binding affinity (KD) to the KRAS G12D protein of 33 nM. It reduces the activity of KRAS G12D (KRAS G12D-GTP), but does not reduce that of KRAS G13D.

     KRAS G12D inhibitor 14 Chemical Structure
  76. GC69340 KRas G12R inhibitor 1

    KRas G12R inhibitor 1 (compound 3) is a selective covalent inhibitor of KRas G12R, which can irreversibly bind to the Switch II region of K-Ras by utilizing the strong nucleophilicity of mutated cysteine. KRas G12R inhibitor 1 can be used for cancer research.

     KRas G12R inhibitor 1 Chemical Structure
  77. GC62486 KRAS inhibitor-10 KRAS inhibitor-10 selectively and effectively inhibit RAS proteins, and particularly KRAS proteins. KRAS inhibitor-10 is an orally active anti-cancer agent and can be used for cancer research, such as pancreatic cancer, breast cancer, multiple myeloma, leukemia and lung cancer. KRAS inhibitor-10 is a?tetrahydroisoquinoline compound (compound 11) extracted from patent WO2021005165 A1. KRAS inhibitor-10 Chemical Structure
  78. GC69341 KRAS inhibitor-3

    KRAS inhibitor-3 is a KRAS inhibitor. It binds with high affinity to both wild-type and oncogenic KRAS mutants (KD: 0.28 μM for KRAS WT, 0.63 μM for KRAS G12C, 0.37 μM for KRAS G12D, and 0.74 μM for KRAS Q61H). Additionally, it disrupts the interaction between KRAS and Raf.

     KRAS inhibitor-3 Chemical Structure
  79. GC60969 KRAS inhibitor-9 KRAS inhibitor-9, a potent KRAS inhibitor (Kd=92 μM), blocks the formation of GTP-KRAS and downstream activation of KRAS. KRAS inhibitor-9 binds to KRAS G12D, KRAS G12C and KRAS Q61H protein with a moderate binding affinity. KRAS inhibitor-9 causes G2/M cell cycle arrest and induces apoptosis. KRAS inhibitor-9 selectively inhibits the proliferation of NSCLC cells with KRAS mutation but not normal lung cells. KRAS inhibitor-9 Chemical Structure
  80. GC73443 Kras4B G12D-IN-1 Kras4B G12D-IN-1 is a Kras4B G12D inhibitor with anticancer effects. Kras4B G12D-IN-1 Chemical Structure
  81. GC73723 KRASG12D-IN-1 KRASG12D-IN-1 (compound 22) is a KRASG12D Inhibitor. KRASG12D-IN-1 Chemical Structure
  82. GC73724 KRASG12D-IN-2 KRASG12D-IN-2 (compound 28) is a KRASG12D Inhibitor. KRASG12D-IN-2 Chemical Structure
  83. GC64447 KRpep-2d KRpep-2d is a potent K-Ras inhibitor and inhibits proliferation of K-Ras-driven cancer cells. KRpep-2d can be used for cancer research. KRpep-2d Chemical Structure
  84. GC65032 KRpep-2d TFA KRpep-2d (TFA) is a potent K-Ras inhibitor and inhibits proliferation of K-Ras-driven cancer cells. KRpep-2d can be used for cancer research. KRpep-2d TFA Chemical Structure
  85. GC61766 LC-2 LC-2 is a potent and first-in-class von Hippel-Lindau-based PROTAC capable of degrading endogenous KRAS G12C, with DC50s between 0.25 and 0.76 μM. LC-2 covalently binds KRAS G12C with a MRTX849 warhead and recruits the E3 ligase VHL, inducing rapid and sustained KRAS G12C degradation leading to suppression of MAPK signaling in both homozygous and heterozygous KRAS G12C cell lines. LC-2 Chemical Structure
  86. GC73607 LUNA18 LUNA18 is an orally-available cyclic peptide KRAS and ERK inhibitor. LUNA18 Chemical Structure
  87. GC10265 Manumycin A

    NSC 62214, UCF 1C

    farnesyltransferase inhibitor

     Manumycin A Chemical Structure
  88. GC32970 MBQ-167 MBQ-167 is a dual Rac/Cdc42 inhibitor, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively. MBQ-167 Chemical Structure
  89. GC36599 Methylophiopogonanone B An isoflavone with diverse biological activities Methylophiopogonanone B Chemical Structure
  90. GC73998 MK-1084 MK-1084 is a selective KRAS G12C inhibitor that is currently in Phase I clinical trial (NCT05067283). MK-1084 Chemical Structure
  91. GC14800 ML 141

    CID2950007

     Cdc42 GTPase inhibitor ML 141 Chemical Structure
  92. GC13315 ML-098

    CID-7345532

     activator of the GTP-binding protein Rab7 ML-098 Chemical Structure
  93. GC61076 MLS000532223 MLS000532223 is a high affinity, selective inhibitor of Rho family GTPases, with EC50 values ranging from 16 μM to 120 μM. MLS000532223 prevents GTP binding to several GTPases. MLS000532223 Chemical Structure
  94. GC69498 MRTF/SRF-IN-1

    MRTF/SRF-IN-1 (example 41) is an inhibitor of myocardin-related transcription factor and serum response factor (MRTF/SRF). MRTF/SRF-IN-1 can be used for research on cancer prevention and fibrosis.

     MRTF/SRF-IN-1 Chemical Structure
  95. GC64964 MRTX-1257 MRTX-1257 is a selective, irreversible, covalent and orally active KRAS G12C inhibitor, with an IC50 of 900 pM for KRAS dependent ERK phosphorylation in H358 cells. MRTX-1257 Chemical Structure
  96. GC64452 MRTX-EX185 MRTX-EX185 is a potent inhibitor of GDP-loaded KRAS and KRAS(G12D), with an IC50 of 90 nM for KRAS(G12D). MRTX-EX185 also binds GDP-loaded HRAS. MRTX-EX185 Chemical Structure
  97. GC73115 MRTX-EX185 formic MRTX-EX185 formic is a potent inhibitor of GDP-loaded KRAS and KRAS(G12D), with an IC50 of 90 nM for KRAS(G12D). MRTX-EX185 formic Chemical Structure
  98. GC64365 MRTX0902 MRTX0902 is an orally active and potent SOS1 inhibitor with an IC50 of 46 nM (WO2021127429A1; Example 12-10). MRTX0902 Chemical Structure
  99. GC62699 MRTX1133 MRTX1133 is an exceptionally potent and selective KRASG12D inhibitor with high affinity (<2nM). MRTX1133 Chemical Structure
  100. GC63079 MRTX1133 formic MRTX1133 formic Chemical Structure
  101. GC38400 MRTX849 MRTX849 (Adagrasib) is a highly potent and selective covalent inhibitor of KRASG12C, with an IC50 value of 5nM. MRTX849 Chemical Structure

Items 1 to 100 of 139 total

per page
  1. 1
  2. 2

Set Descending Direction